Trial profile Luc F Van Gaal, Lancet 2005;365:1389

Baseline characteristics Luc F Van Gaal, Lancet 2005;365:1389

Change from baseline in bodyweight (A) and waist circumference (B) Luc F Van Gaal, Lancet 2005;365:1389

Changes in metabolic and cardiovascular risk factors in ITT population Part I Luc F Van Gaal, Lancet 2005;365:1389

Changes in metabolic and cardiovascular risk factors in ITT population Part II Luc F Van Gaal, Lancet 2005;365:1389

Changes in metabolic and cardiovascular risk factors in ITT population Part III Luc F Van Gaal, Lancet 2005;365:1389

Changes in selected metabolic and cardiovascular risk factors in patients who completed 1 year follow-up Part I Luc F Van Gaal, Lancet 2005;365:1389

Changes in selected metabolic and cardiovascular risk factors in patients who completed 1 year follow-up Part II Luc F Van Gaal, Lancet 2005;365:1389

Changes in selected metabolic and cardiovascular risk factors in patients who completed 1 year follow-up Part III Luc F Van Gaal, Lancet 2005;365:1389

Proportion of patients who lost 5% and 10% of baseline weight at 1 year *p<0.001 vs placebo. †p=0.002 vs placebo. Luc F Van Gaal, Lancet 2005;365:1389

Mean percentage change from baseline in HDL-cholesterol (A) and triglycerides (B) *p<0.001 vs placebo. †p=0.002 vs placebo. Luc F Van Gaal, Lancet 2005;365:1389

Prevalence of the metabolic syndrome in the ITT and completer populations at baseline and after 1 year of treatment Luc F Van Gaal, Lancet 2005;365:1389

Patients reporting adverse events (≥5% in any treatment group) Luc F Van Gaal, Lancet 2005;365:1389

Serious adverse events by system organ class during the double-blind period of the trial Luc F Van Gaal, Lancet 2005;365:1389

Patients reporting adverse events leading to discontinuation Luc F Van Gaal, Lancet 2005;365:1389

Hypothetical model of role of central and peripheral components of endocannabinoid system in regulation of food intake and peripheral metabolism Luc F Van Gaal, Lancet 2005;365:1389